The registries

The research the CGD Society (CGDS) funds is at the cutting edge, often exploring solutions that will take many years to refine and apply clinically. Research that helps CGD sufferers can benefit millions more because it is a single-gene deficiency, meaning any breakthroughs in CGD are more likely to shed light on how other genetic disorders work.

Our research strategy

To date, CGDS has awarded more than 50 grants. Our awards have ranged from a few hundred pounds to cover travel costs to the support of a programme grant. We support both basic science and applied medical research, and strongly encourage collaboration between our researchers.

Over the period 2015 - 2018 we will be making available £50,000/year in grant funds.

You can read our research strategy here.

The Chronic Granulomatous Disorder Society is a member of the Association of Medical Research Charities (AMRC). All AMRC members support the AMRC position statement on the use of animals in research.

Facts about our funding process

  • Peer review is central to our grant awarding process
  • We have no geographical restrictions on where we fund
  • All full applications undergo external peer review
  • A minimum of 3 external reviewers are used per application
  • The mean success rate for full applications received between 2008 to 2011 applications was 23%
  • We abide by the AMRC’s principles of peer review.

Key target areas for funding

CGDS funds research into the cause, inheritance, diagnosis, management and treatment of CGD. It is willing to consider research applications of high quality that address important scientific, clinical or social questions relating to CGD. The criteria for funding are excellent science and relevance to and benefit for CGD.

Priority research and scientific areas

CGDS is committed to providing funding in the following areas:

  • Gene and cellular therapy for CGD as a treatment and potential cure for CGD
  • Causes and treatment of inflammation in CGD. Understanding the mechanisms involved and improving treatment methods
  • Causes and treatment of infection in CGD. The mechanisms involved and improving methods of treatment
  • Basic research concerning the structure and function of the enzyme NADPH oxidase and identification of possible target pathways for therapeutic intervention

The grant application process

There is only one round of grant funding each year and a call for proposals is made in the journal 'Nature' and through our network of professional members throughout the world.  Anyone interested in applying for a CGD research grant has to first complete a preliminary application. This gives details of the proposed work, its relevance to CGD and approximate costings for the work. These preliminary applications are reviewed by members of our medical panel and lay reviewers from our Trustee board who rate the applications according to relevance to the charity’s research strategy and whether the science is likely to lead to benefit for the CGD community. At this stage approximately 30-50% of the applications are rejected. Successful applicants are then asked to submit a full application.

How we decide on funding

Three external independent experts with related research experience reviews each application. Independent experts are chosen that have no affiliation to the grant applications and are asked to declare any conflict of interest in being a reviewer before receiving an application. All reviewers are expected to respect the applicants' confidentiality. The CGDS provides guidance to the referees and supplies them a review form for this process. Peer reviewers are asked to score the applications on the basis of quality, relevance, originality, feasibility and value for money.
 The CGDS Medical Advisory Panel consider the external reviewers' recommendations. The panel advises CGDS on the best quality research to fund and on setting priorities for future CGD research. We have in place a code of practice and conflict of interest policy and a register of interests for our Research Advisory Panel by which all members agree to abide before joining the panel. Panel members can serve up to a maximum of six years on the panel.
 The AMRC approves all our peer review methods and in 2011 the CGD Society received a certificate of best practice for its peer review procedures.

Selecting the most promising projects

It is the nature of research that some avenues yield no useful results, but the CGDS is very careful where donors’ money is spent. Every application received is fully peer reviewed by external experts who pass on their advice to our dedicated Advisory Panel. This Panel then decides which projects would give the best scientific outcomes for CGD and the best value for money.

Equally important, we demand absolute clarity regarding how grant funds were spent, and monitor and evaluate carefully. As part of this process it is a condition of receiving a CGDS research grant that a research grant award report is submitted annually and final reports are submitted within three months from the end of the grant. Reports are assessed by members of the Research Advisory Panel or may be sent to other specialist advisors. Comments arising from the assessment will be made available to the grant holder.

CGDS: Our integrity

We are well connected with the biggest names in research in our field; with key hospitals, research establishments, scientists and medical professionals. We keep up a dialogue with other top bodies to maximise impact and avoid duplication of research. We are transparent and accountable, and are happy to provide details or exactly how research projects spent the money you gave us.

CGDS awards

The purpose of these awards is to provide support for a time-limited project designed to answer a single question or a small group of related questions. Such questions must be directed towards furthering our understanding of CGD and/or developing effective treatments for the condition that fit within the priority areas.

Important notes for applicants

Before a full application can be considered the applicant(s) and the institution must sign a form stating that they will accept and adhere to the CGDS Terms and Conditions for Awards in the event of an award being made. Otherwise the application will not be considered. The CGDS will not enter into negotiation regarding this matter.

Please read our Notes for Applicants and our Terms and Conditions of Grant before applying to the CGDS. Make sure your application is relevant to our research strategy.

Our Research Advisory Panel

Read more about our research advisory panel here

  • Professor Len Seymour, Chair of Committee, Professor of Gene Therapies, University of Oxford
  • Dr Siobhan Burns, Reader and Consultant in Immunology, University College London, Institute of Immunity and Transplantation
  • Dr Tayfun Güngör, Head, Stem Cell Transplantation Department (SCT), University Children`s Hospital, Zurich, Switzerland
  • Dr Steven Howe, Senior Research Associate, Molecular Immunology Unit, Institute for Child Health, London
  • Professor Tom Rogers, Head of Clinical Microbiology, Trinity College Dublin, St James's Hospital, Dublin
  • Professor Dirk Roos, Department of Blood Cell Research, Sanquin Research Centre, Amsterdam
  • Professor Adriano Rossi, Chair of Respiratory and Inflammation Pharmacology at the University of Edinburgh/MRC Centre for Inflammation Research
  • Dr Simon Travis, Clinical Director of Gastroenterology and Endoscopy, John Radcliffe Hospital, Oxford
  • Dr Adilia Warris, Institute of Medical Sciences, University of Aberdeen
  • Andrew Orchard, CGD Society Trustee